- Home
- QSR vs INCY Comparison
QSR vs INCY Comparison
Compare QSR & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QSR | INCY |
|---|---|---|
| Founded | 1954 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9B | 23.7B |
| IPO Year | 2014 | 1994 |
Fundamental Metrics
Financial Performance| Metric | QSR | INCY |
|---|---|---|
| Price | $78.08 | $118.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 28 | 28 |
| Target Price | $85.32 | ★ $130.92 |
| AVG Volume (30 Days) | ★ 2.7M | 1.9M |
| Earning Date | 10-29-2026 | 10-29-2026 |
| Dividend Yield | ★ 3.31% | N/A |
| EPS Growth | N/A | ★ 4173.33 |
| EPS | ★ 3.95 | 0.50 |
| Revenue | ★ $9,434,000,000.00 | $3,394,635,000.00 |
| Revenue This Year | $4.30 | $17.47 |
| Revenue Next Year | $0.20 | $4.45 |
| P/E Ratio | ★ $19.84 | $245.70 |
| Revenue Growth | 12.23 | ★ 13.67 |
| 52 Week Low | $65.43 | $89.25 |
| 52 Week High | $81.96 | $132.60 |
Technical Indicators
Market Signals| Indicator | QSR | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 64.98 | 60.14 |
| Support Level | $77.33 | $120.79 |
| Resistance Level | $81.81 | $130.53 |
| Average True Range (ATR) | 1.83 | 3.74 |
| MACD | 0.34 | 1.12 |
| Stochastic Oscillator | 95.32 | 96.10 |
Price Performance
Historical ComparisonAbout QSR Restaurant Brands International Inc.
Restaurant Brands generates about $47 billion in system sales across more than 33,000 restaurants in over 120 markets, making it one of the largest restaurant companies globally. Its banners include Burger King (7,025 stores), Tim Hortons (4,586), Popeyes (3,578), and Firehouse Subs (1,449), concentrated in the US and Canada; these brands also comprise 16,403 franchised international locations as of year-end 2025. Restaurant Brands primarily earns revenue from franchise and property fees, supply chain sales within the Tim Hortons segment, company-operated restaurants, and advertising royalties.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.